Home / Awards / Scrip Awards 2022
VIEW THE WINNERS
Scrip Awards 2022
30 Nov 2022 - 18:30 - 00:00
Royal Lancaster Hotel, London
Abstract blue and green spiral.

Sponsored By

About this award 

Now in its 18th year, the Scrip Awards brings together over 400 industry leaders to celebrate and recognise the very best innovations and achievements in global biopharma. Winners will be celebrated across 15 categories, covering a full spectrum of advancements, from Best New Drug, Community Partnership of the Year, Clinical Advance of the Year and Best Contract Research Organisation.

All Awards entries will be carefully reviewed by an independent Judging Panel - a group of senior industry experts from around the world, handpicked for their experience and objectivity. This prestigious annual event of networking and celebration will incorporate a gala black-tie dinner and Awards ceremony, on Wednesday 30 November at the Royal Lancaster Hotel, London.

 

Key details 

  Ceremony, Wednesday, 30 November, 2022

  Free to Enter

  Royal Lancaster, London

THE SCRIP AWARDS WINNERS 2022

The Best New Drug Award recognises excellence in pharmaceutical development. Launching innovative new products is the most important function of the industry, and a successful new drug launch marks the culmination of years of risky and expensive R&D.

WINNER:

Immunocore’s Kimmtrak (tebentafusp) for metastatic uveal melanoma

Watch the winners interview here

NOMINEEES:

  • Agios Pharmaceuticals’ Pyrukynd (mitapivat) for pyruvate kinase deficiency
  • Argenx’s Vyvgart (efgartigimod alfa) for generalized myasthenia gravis
  • Immunocore’s Kimmtrak (tebentafusp) for metastatic uveal melanoma
  • Legend Biotech/Janssen Biotech’s Carvykti (ciltacabtagene autoleucel) for multiple myeloma
  • Mirum Pharmaceuticals’ Livmarli (maralixibat) for cholestatic pruritus in patients with Alagille syndrome
  • Servier Pharmaceuticals’ Tibsovo (ivosidenib tablets) for cholangiocarcinoma with an IDH1 mutation

This Award seeks to recognise success in a clinical trial of a new drug product (biological or chemical) which is expected to lead to an advance in healthcare. This might include the first demonstration of a clear clinical effect for a new drug in an area of unmet medical need, a pivotal study of a new drug with a breakthrough mechanism of action, or a major study of a potential new or expanded indication for an already marketed product.

WINNER:

Daiichi Sankyo and AstraZeneca’s Phase III DESTINY-Breast04 trial of Enhertu in breast cancer

Watch the winners interview here

NOMINEES:

  • Boehringer Ingelheim and Eli Lilly’s Phase III EMPEROR-Preserved trial of Jardiance in heart failure
  • Daiichi Sankyo and AstraZeneca’s Phase III DESTINY-Breast04 trial of Enhertu in breast cancer
  • Intellia Therapeutics’ Phase Itrial of NTLA-2001for transthyretin amyloidosis
  • Janssen Oncology’s Phase I/II MajesTEC-1 study of teclistamab in multiple myeloma
  • Lumosa Therapeutics’ Phase IIa study of LT3001 for stroke
  • Servier’s Phase III AGILE trial of Tibsovo in IDH1-mutated AML

The biotech industry’s entrepreneurial spirit and cutting-edge science have transformed the research and development of medicines in the past few decades. This Award honours outstanding achievement by biotech companies

WINNER:

Moderna

Watch the winners interview here

NOMINEES:

  • Bicycle Therapeutics
  • Immunocore
  • Moderna
  • Qlaris Bio
  • Redx Pharma
  • SparingVision

Scrip’s China Biopharma Leadership Award reflects on the rapid maturing of China’s biopharma sector - thanks to the development of Homegrown biopharma companies, CDMOs, and increasing investment from global multinational biopharma companies. The category seeks to reward firms that have shown leadership in developing China’s biopharma sector through significant commercial and R&D activity, and by helping patients access new treatments, through new launches and successful negotiations with China’s healthcare payers and clinical leaders.

WINNER:

BeiGene China

NOMINEES:

To enter this category, please answer the following:

  • Anticancer Bioscience
  • BeiGene China
  • Brii Biosciences
  • Clover Biopharmaceuticals
  • Everest Medicines

This Award is designed to acknowledge the numerous ways in which pharma and biotech companies give back to the wider community. This could include outreach within a local community, with a charity or patient advocacy group, or alongside an NGO or humanitarian organisation.

WINNER:

Regeneron and the Society for Science’s Science Talent Search initiative

Watch the winners interview here

NOMINEES:

  • Agios Pharmaceuticals’ RISE UP clinical trial recruitment campaign with Sickle Cell Warriors
  • AstraZeneca's Young Health Programme in partnership with Plan International UK for the Girls Belong Here campaign
  • AstraZeneca and Deloitte’s Non-Executive Director Programme
  • PHASTAR and the Florence Nightingale Museum
  • Regeneron and the Society for Science’s Science Talent Search initiative

Scrip’s Executive of the Year Award is designed to acknowledge excellence in the leadership of large and small pharmaceutical and biotechnology companies.

WINNER:

Executive Of The Year – Companies with a market cap >$7bn

Stéphane Bancel, Chief Executive Officer of Moderna

Executive Of The Year – Private companies and those with a market cap <$7bn

Michael M Morrissey, President and Chief Executive Officer of Exelixis

NOMINEES:

Executive Of The Year – Companies with a market cap >$7bn

  • Stéphane Bancel, Chief Executive Officer of Moderna
  • Yvonne Greenstreet, Chief Executive Officer of Alnylam Pharmaceuticals
  • Ying Huang, Chief Executive Officer of Legend Biotech
  • Husseini Manji, Global Head of Johnson & Johnson Science for Minds
  • Christi Shaw, Chief Executive Officer of Kite, a Gilead Company
  • Jan van de Winkel, President & Chief Executive Officer of Genmab

Executive Of The Year – Private companies and those with a market cap <$7bn

  • Renée Aguiar-Lucander, Chief Executive Officer of Calliditas Therapeutics
  • Stéphane Boissel, Chief Executive Officer and Chairman of SparingVision
  • Scott Braunstein, Chief Executive Officer of Marinus Pharmaceuticals
  • Bahija Jallal, Chief Executive Officer of Immunocore
  • John Leonard, President and Chief Executive Officer of Intellia Therapeutics
  • Michael M Morrissey, President and Chief Executive Officer of Exelixis

Licensing is vital both in helping to keep pharma’s pipelines replenished and in generating income for smaller firms. Deals considered here are those that involve the licensing of a particular drug, project or group of drugs/projects from one company to another for further development and/ or marketing.

WINNER:

GSK and Alector for the development and commercialization of AL001 and AL101for neurodegenerative diseases

Watch the winners interview here

NOMINEES:

  • Accord Healthcare with Myovant Sciences to commercialize Orgovyx(relugolix) for advanced hormone-sensitive prostate cancer
  • AstraZeneca and Ionis Pharmaceuticals for the development and commercialization of eplontersen for TTR amyloidosis
  • GSK and Alector for the development and commercialization of AL001 and AL101for neurodegenerative diseases
  • iTeos and GSK for the development and commercialization of EOS-448 (GSK4428859A) for solid tumors
  • RQ Biotechnology and AstraZeneca for novel monoclonal antibodies targeting SARS-CoV-2
  • Sunovion Pharmaceuticals (Sumitomo Pharma) and Otsuka Pharmaceutical to jointly develop and commercialize ulotaront, non-racemic amisulpride, SEP-378614 and SEP-380135

Scrip’s Business Development Team of the Year Award will honour the achievements of business development teams whether they are from a pharma or biotech company or a cross-company team responsible for a specific deal or collaborative project.

WINNER:

Synaffix’s Business Development Team

Watch the winners interview here

NOMINEES:

  • Beam Therapeutics’ Business Development Team
  • Domainex’s Business Development and Commercial Team
  • Healiva’s Business Development Team
  • Sanofi Partnering Team
  • Synaffix’s Business Development Team
  • Takeda's Center for External Innovation

The Award for the Best Contract Research Organization acknowledges the critical role that CROs play in drug development. Outsourcing is vital as the pharmaceutical industry seeks to benefit more and more from these specialist companies’ experience in handling all aspects of clinical trials and other research.

WINNER:

ICON

Watch the winners interview here

NOMINEES:

  • Altasciences
  • CMIC Group
  • ICON
  • IQVIA
  • Novotech
  • Parexel
  • PPD, Part of Thermo Fisher Scientific
  • Syneos Health

The Award for the Best Contract Research Organisation acknowledges the critical role that CROs play in drug development. Outsourcing is vital as the pharmaceutical industry seeks to benefit more and more from these specialist companies’ experience in handling all aspects of clinical trials and other research.

WINNER:

Veramed

Watch the winners interview here

NOMINEES:

  • Cellomatics Biosciences
  • CluePoints
  • Crown Bioscience
  • MAC Clinical Research
  • Medical Research Network
  • MMS Holdings
  • PHASTAR
  • Veramed

Scrip’s Best Partnership Alliance Award recognises the importance of pharmaceutical and/ or biotech companies working together to develop new medicines. This category seeks to reward innovative partnerships between companies in which they share the risks and rewards inherent in developing new drugs.

WINNER:

GRAIL and AstraZeneca for the research, development and commercialization of companion diagnostic assays for early-stage cancer

Watch the winners interview here

NOMINEES:

  • Amgen and Arrakis Therapeutics for the discovery of RNA degraders
  • GRAIL and AstraZeneca for the research, development and commercialization of companion diagnostic assays for early-stage cancer
  • Merck KGaA and Amphista Therapeuticsto discover and develop small-molecule protein degraders in oncology and immunology indications
  • Recursion and Roche/Genentech to use Recursion’sAI Operating System and Maps of Biologyto identify novel biological relationships in neuroscience and oncology
  • Sanofi and IGM Biosciencesfor engineered IgM antibodies in oncology and immunology/inflammationtargets
  • SparingVision and Intellia Therapeuticsto develop novel genomic medicines using CRISPR/Cas9 technology for ocular diseases

This Scrip Award seeks to reward successful and creative fundraising by pharma and biotech companies. The investment can come in a variety of guises from grants and public private partnership deals to venture fundraising and public offerings but should be earmarked for use in drug discovery and/or development.

Winner:

SalioGen Therapeutics’$130m Series B financing

NOMINEES:

  • Engitix Therapeutics’ $54m Series A financing
  • Mestag Therapeutics’ $45m seed funding
  • Microbiotica’s£50m Series B financing
  • OMass Therapeutics’ $100m Series B financing
  • Precirix’s€80m Series B financing
  • SalioGen Therapeutics’$130m Series B financing

This category will acknowledge and celebrate the outstanding scientific or technological breakthrough which the judging believes has the potential to be transformative in the discovery or development of new medicines.

Winner:

Orca Bio’s Orca-Tcell therapy

NOMINEES:

  • 3DBio’s AuriNovo patient-matched, 3D-bioprinted living tissue ear implant
  • BenevolentAI’sBenevolent Platform with Benevolent Knowledge Graph
  • Evonetix’s desktop platform for DNA synthesis
  • Nucleome Therapeutics’ genome dark matter platform technology
  • Orca Bio’s Orca-Tcell therapy
  • Quris BioAI Clinical Prediction Platform

The Pharma Company of the Year Award honours outstanding achievements by pharmaceutical companies over the qualifying 12 months between 1 June 2021 - 30 June 2022.

Winner:

Novo Nordisk

Watch the winners interview here

NOMINEES:

The winner of this Award will be an exceptional individual with a consistent history of service, above and beyond the call of duty, throughout their career. This prestigious international Award will go to someone who has had a distinguished career in the biotech or pharmaceutical arena, primarily within industry.

Winner:

Mads Øvlisen

NOMINEES:

HEADLINE SPONSOR

ICON plc is a world-leading healthcare intelligence and clinical research organisation, with over 38,000 employees in 93 locations in 46 countries around the world, headquartered in Dublin. We advance clinical research by providing outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device, and government and public health organisations. Our services span the entire lifecycle of product development, from molecule to medicine, across a broad range of therapeutic areas. We develop new innovations, drive emerging therapies forward, and improve patient lives.

 
OUR 2022 SPONSORS
Parexel
Parexel is among the world’s largest clinical research organizations (CROs), providing the full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. Leveraging the breadth of our clinical, regulatory and therapeutic expertise, our team of more than 21,000 global professionals works in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind, increasing access and participation to make clinical research a care option for anyone, anywhere.
MSD
MSD has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. Our scientific advances have made a difference in the lives of millions of patients worldwide. From MSD’s development of the first measles and mumps vaccines to treatments for cancer and diabetes, we are an industry leader in bringing forth innovative new medicines. In 2019 MSD had sales of more than $46 billion and we operate in more than 140 countries.
Quris ai
Quris-AI is an artificial intelligence innovator that is disrupting the drug development process. Quris' Bio-AI Clinical Prediction Platform better predicts which drug candidates will safely work in humans, avoiding tremendous costs of failed clinical trials. We are led by a team of top scientists and strategic investors and are actively preparing for clinical testing with our first AI-based drug.
WuXi AppTec
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the pharmaceutical and healthcare industry around the world to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, and cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization),helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received AA ESG rating from MSCI in 2023 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."
IQVIA
IQVIA Consumer Health is a leading global provider of actionable insights, purpose-built technologies and exceptional market expertise to the consumer healthcare industry. IQVIA Consumer Health harnesses data from more than 80 countries to co-create and execute tailored initiatives for every stage of the concept-to-consumer journey. Utilizing IQVIA Connected Intelligence, we deliver specialized and actionable insights combining analytics, technology and domain expertise to help consumer healthcare organizations adapt and innovate fast to an ever-changing market, flawlessly navigate regulatory environments and engage effectively with customers and consumers.
Thermo Fisher Scientific
WCG
WCG is a true partner to research sponsors, CROs, sites and participants in navigating the clinical research journey.
Leveraging our strong relationships, deep domain expertise, connected technology, and data intelligence we expand access, and enhance the quality, efficiency, and safety required to successfully advance research that saves and improves lives.
Avance Clinical
Avance Clinical is a premium full-service Contract Research Organisation (CRO) based in Australia, New Zealand and North America, providing high-quality clinical research services to the international drug development industry which brings innovative new drugs to patients. Avance Clinical has more than 260 staff and has backing from the private equity group, Riverside Company, to support global expansion plans.

Avance Clinical offers clinical project management, trial monitoring, regulatory support, safety reporting, scientific and medical writing, data management, statistical and pharmacokinetic services, and external clinical auditing. We operate to the highest standards of compliance required by global regulatory agencies such as the FDA to ensure acceptance of data for drug approvals.

Our clients are international biotech companies in their early phases of drug development that require fast, agile, and adaptive solution-oriented clinical research services. The company uses state-of-the-art technology, gold standard systems, and deep scientific expertise to provide clients with the most successful outcomes.

The Avance Clinical team offers exceptional study approval and success rates which can be attributed to its deep scientific expertise, advanced data technologies, knowledge of the Australian, New Zealand and North American regulatory environment, and its extensive relationships with sites and KOLs.
Want to sponsor an award
Awards Judges
AJIT DANGI
Founder, President and Chief Executive Officer
Danssen Consulting
ANDY SMITH
Life Science Analyst
Equity Development
PETER PITTS
President
Center for Medicine
PHORNVIT PHACHARINTANAKUL
Chairman
Strategic Business Partners
TREVOR JONES
Director
E-Therapeutics
VAIDHEESH ANNASWAMY
Chief Executive Officer
North Star Asia
Headshot of Mads Ovlisen.
MADS ØVLISEN
Ex-President and CEO
Novo Nordisk
BRIAN TEMPEST
Editor In Chief
Journal of Generic Medicines
ROBERT SPIEGEL
Founder
Spiegel Consulting
LAURA BROWN
Director, LB Training and Development
University of Cardiff and a Training and QA Consultant.
LAURIE HALLORAN
President & CEO
Halloran Consulting Group, Inc.
BRIAN HARGREAVES
Independent Advisor
VIREN MEHTA
Founder
Mehta Partners
Headshot of Alison Messom.
ALISON MESSOM
Senior Director Clinical Operations
MiroBio
KATE BINGHAM
Managing Partner
SV Health Managers
AJIT DANGI
Founder, President and Chief Executive Officer
 Danssen Consulting
Dr. Ajit Dangi is President & CEO of Danssen Consulting, a strategy firm specialising in Life Sciences and Healthcare. He has served as the Chairman of the Board of Fulford India Ltd., a subsidiary of Merck & Co. Inc. USA for ten years. He is also Director of Atul Bioscience Ltd. India. Dr. Dangi has served as President & Executive Director of Johnson & Johnson India Ltd . where he worked for twenty years in various capacities. He has also served as Director General of Organisation of Pharmaceutical Producers of India (OPPI) for over seven years.

Dr. Dangi is a Graduate in Chemistry from University of Bombay and later earned his Masters and Doctorate ( Ph.D. ) degrees in Pharmaceutical Chemistry from University of London , England . He has also undergone Advanced Management Program from Kellogg Graduate School of Business, Chicago, USA.

Dr. Dangi is a Graduate in Chemistry from University of Bombay and later earned his Masters and Doctorate ( Ph.D. ) degrees in Pharmaceutical Chemistry from University of London , England . He has also undergone Advanced Management Program from Kellogg Graduate School of Business, Chicago, USA.
ANDY SMITH
Life Science Analyst
 Equity Development
Smith began his career as a scientist in the research and development division of ICI and then SmithKline Beecham. After completing his PhD in Molecular Biology at the University of Nottingham and Glaxo, and after then an MBA, Smith switched to a commercial role at SB Pharmaceuticals and was appointed global brand manager for Bactroban and new products in Anti-Infectives Strategic Product Development (SPD). In 2000, Smith moved into asset management and venture capital at 3i Group and subsequently held the position of lead fund manager for four life science specific funds – 3i Bioscience Investment Trust PLC, International Biotechnology Trust PLC, and AXA Framlington Biotech Fund. Smith was awarded the Techmark technology fund manager of the year for 2007.

After leaving AXA in 2010, Smith held appointments as director of business development at the Oxfordshire Bioscience Network and head of corporate finance at PharmaVentures. Smith has also taught the life science company valuation, finance and analysis module on the University of Cambridge MPhil program for over ten years. Smith returned to specialist fund management in 2012 to manage the Magna Biopharma Income Fund.

In 2017 Andy moved to the Pricing & Market Access group at ICON in London where he advised big pharma and smaller life science companies on the valuation and commercialisation of their products and returned to the City at the end of 2017 to work at Edison.
PETER PITTS
President
 Center for Medicine
Peter Pitts is a Visiting Professor at the University of Paris Medical School and President of the Center for Medicine in the Public Interest. He is a former member of the United States Senior Executive Service and Associate Commissioner of the US Food & Drug Administration. Pitts is a member of the Council for International Organizations of Medical Sciences (CIOMS) Expert Working Group to help advance patient involvement in the development and safe use of medicines. (CIOMS is an international, non-governmental, non-profit organization established jointly by WHO and UNESCO in 1949.) He is the lead author of many professional peer reviewed publications including the Lancet, Therapeutic Innovation and Regulatory Science, and Nature Biotechnology. He is an Associate Editor of Therapeutic Innovation & Regulatory Science (the official DIA journal), a member of the External Advisory Board, IMS Institute for Healthcare Informatics in Asia, Executive Advisory Board, the Galien Foundation, Editorial Advisory Board, Food and Drug Policy Forum, Advisory Board, Journal of Commercial Biotechnology and a member of the Editorial Advisory Board of The Patient Magazine. Pitts lives in New York City.
Specific areas of global policy expertise include FDA policy and process, healthcare technology assessment and reimbursement issues, real world evidence, social media, off label-communications, pharmacovigilance, patient-focused drug development, abuse-deterrent opioids, biosimilar development, Rx-to-OTC switching, risk management plans, GMP policies, pharmacy education programs, drug safety, Critical Path, personalized medicine, clinical trial transparency, IP protection, FDA reform, drug importation, counterfeiting, genetically modified food issues, food safety and security, recalls, nutritional labeling.
PHORNVIT PHACHARINTANAKUL
Chairman
 Strategic Business Partners
TREVOR JONES
Director
 E-Therapeutics
Jones is chairman of the Oxford-based AI drug discovery company e-Therapeutics and a member of the board of the USA vaccine company Techimmune LLC. He was formerly R&D Director of the Wellcome Foundation, a director of Allergan Inc. and Director General of the Association of the British pharmaceutical industry (ABPI ). He is a visiting professor at Kings College London
VAIDHEESH ANNASWAMY
Chief Executive Officer
 North Star Asia
Strong business leadership track record of over 35 years in Health care and FMCG industries in multi countries focusing on sustainable and responsible growth in J&J and GSK.
Currently CEO North Star Asia LLP, Management Consultant and Senior Advisor, PAG Holdings Hong Kong. Mr. Vaidheesh was also previously MD and VP (South Asia), GSK.
Created new business models and markets, turned around declining businesses, flourished in various leadership situations. Winner of Economics Times award as the “Most Promising Asian Leader of the year -2016”. Won the prestigious Michel Porter award for “Shared value-2016”. President of OPPI 2017-2020. Winner of the prestigious Fair business practices Trophy. Signed and executed MOU with China Communist Party School for health care initiatives for J&J. Honorary Fellow of the Minimal Access Surgeons Association of India.
MADS ØVLISEN
Ex-President and CEO
 Novo Nordisk
Until 2000, Mads Øvlisen was President and CEO of Novo Nordisk A/S, Denmark, and served as its chair until 2006. His board positions included the chairmanship of LEGO A/S, Bang & Olufsen A/S, the Royal Danish Theatre, the Danish Arts Council, the Danish Council on Corporate Social Responsibility, and the Danish Mediation and Complaints-Handling Institution for Responsible Business Conduct (the Danish OECD national contact point).
He was a member of the board of United Nations Global Compact, chaired the Compact’s advisory group on supply chain sustainability and was a professor of corporate social responsibility at the Copenhagen Business School.
BRIAN TEMPEST
Editor In Chief
 Journal of Generic Medicines
Dr Brian Tempest has held many Non-Executive roles in the Corporate, Educational and NGO Sectors. These positions include Pharmaceuticals, Hospital Management, Medical Diagnostics, Packaging, Financial Services, University Advisory Boards and the United Nations Patent Pool. He is currently Non-Executive Chairman of Touch Medical Media Group Holdings in the UK and is on the Board of a number of international Healthcare Companies as well as advising others from Europe and Asia.
Brian has previously worked for GSK, Pfizer, Sanofi and Sun Pharmaceuticals in leadership positions. He holds FRSC, FRSM, BSc, PhD and DSc qualifications and now resides in Wales, UK.
ROBERT SPIEGEL
Founder
 Spiegel Consulting
LAURA BROWN
Director, LB Training and Development
  University of Cardiff and a Training and QA Consultant.
Dr Brown has held a number of international and senior management positions in the pharmaceutical industry. She has worked for several international companies including GlaxoWellcome, Hoechst Marion Roussel and Phoenix International.

She was a member of the Editorial board of the Good Clinical Practice Journal for 10 years. She is author of several books including Project Management for the Pharmaceutical Industry, a Practical Guide to the Clinical Trial Directive and several articles on the new EU Clinical Trial Regulation.
LAURIE HALLORAN
President & CEO
 Halloran Consulting Group, Inc.
Laurie Halloran founded Halloran Consulting Group in 1998, originally operating out of an unfinished bathroom. Her time as a pediatric ICU nurse had inspired her to start a company that helps move new therapies through FDA processes to get them into the hands of patients desperately in need. By providing a strategic development team, innovative start-up companies could have access to world-class expertise at a fraction of the cost. Since its humble beginnings, Halloran has grown into a successful consultancy of like-minded experts who are dedicated to improving human health by making life science companies better at what they do.
BRIAN HARGREAVES
Independent Advisor
 
VIREN MEHTA
Founder
 Mehta Partners
Viren founded and is managing member of Mehta Partners, LLC. His analytical insights on global health care have influenced biopharmaceutical strategy and investments worldwide. Educated at the University of Southern California (Doctor of Pharmacy) and UCLA (MBA in international finance and marketing), he has worked with senior BioPharma leaders and investment managers for over 30 years.
Gather Health has been one of Viren’s recent initiatives to empower patients while enhancing physician productivity. Gather Health aims to bring together patient’s providers and patient’s personal network, enabling patient to get real-time and active resources and motivation from this team to improve outcomes.
Viren's biopharma strategic advisory work focuses on refining the business model to expand global healthcare access, and to help the bio-pharmaceutical industry succeed globally. His philanthropic work in ecology and education through viram Foundation includes board role with Project Hope (Washington DC) and the Venice Family Clinic (Los Angeles, CA).
Viren began his career at Merck & Co. in international strategic planning and competitor analysis. This foundation prompted Wood MacKenzie & Company Inc. to invite him to establish a pharmaceutical research function in New York. This effort was expanded at S.G. Warburg & Company, and led to the formation of the BioPharma investment advisory group Mehta and Isaly. Now known as Mehta Partners, with a 30-year record, Viren continues to focus on helping refine investment strategy to achieve global growth while enhancing access to healthcare innovations.
ALISON MESSOM
Senior Director Clinical Operations
 MiroBio
A molecular geneticist by training, Dr. Alison Messom has nearly 20 years of industry experience, working both within Pharmaceutical Companies and Clinical Research Organisations and is the current Chairman of the Board of Directors of the ICR.
With detailed experience of directing global clinical trials, Dr. Messom has worn many different hats during her career. She has had the opportunity to travel far and wide on business; lived in the UK, France and Switzerland, and gained operational experience in over 50 countries and line management in over 30.
During the course of her career she has line managed at all levels from CTAs through to Directors and VPs. At both i3 Research and ICON she helped build a new department of dedicated line managers for CRAs and also Start Up teams. While within the Pharma environment she line managed teams within Study and Project Management, Clinical Supplies, Translational Medicine, Data Management, Statistics, Informatics and IT – showing that line management skills are transferrable across functional areas.
KATE BINGHAM
Managing Partner
 SV Health Managers
Kate Bingham, Managing Partner at life sciences venture capital firm SV Health Investors, co-leads SV’s biotech franchise which has a long history of building companies developing transformational new medicines. SV’s investments have resulted in the launch of twenty drugs for inflammatory and autoimmune disease, blindness and cancer.
In 2021 Kate was awarded a DBE in the Queen’s Birthday Honours for her services as Chair of the UK Vaccine Taskforce, where she led a team of world-class experts with the shared purpose of finding and manufacturing COVID-19 vaccines.
Kate is a board member of the Francis Crick Institute and helped launch the Dementia Discovery Fund. She has a first class degree in Biochemistry from the University of Oxford and an MBA from Harvard Business School (Baker Scholar).
Next Steps
Sponsorship Opportunities
Sponsorship provides a wealth of opportunities, from thought leadership to brand awareness and lead generation. Find out more about the numerous sponsorship opportunities available.